SCHEMBL10325342

SCHEMBL10325342

COc1cc2c(cc1OC)[C@@H](c1ccc3c(c1)OCO3)N(C)CC2

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.50
LMNA P02545 4/20 0.49
KDM4E B2RXH2 3/20 0.47
KMT2A Q03164 2/20 0.47
TDP2 O95551 1/20 0.47
POLB P06746 1/20 0.47
MAPT P10636 1/20 0.47
RAD52 P43351 1/20 0.47
CASP6 P55212 1/20 0.47
KCNN2 Q9H2S1 4/20 0.47
KCNN3 Q9UGI6 4/20 0.47
KCNN1 Q92952 2/20 0.47
ADRA1A P35348 2/20 0.47
ADRB1 P08588 1/20 0.47
ADRA2A P08913 1/20 0.47
DRD2 P14416 1/20 0.47
ADRA2B P18089 1/20 0.47
ADRA2C P18825 1/20 0.47
DRD1 P21728 1/20 0.47
DRD4 P21917 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10325499 1.00 MAOA (0.50) MAOALMNAKDM4EKMT2ATDP2
SCHEMBL10325455 1.00 MAOA (0.50) MAOALMNAKDM4EKMT2ATDP2
SCHEMBL6130887 0.88 DRD2 (0.53) LMNAKDM4EKMT2AADRA1ADRD2
SCHEMBL16971018 0.86 ACHE (0.47) LMNAKMT2ADRD2DRD1MEN1
SCHEMBL15557948 0.85 HCRTR1 (0.47) LMNAKMT2AMAPTDRD2DRD1
SCHEMBL16979267 0.84 LMNA (0.46) LMNAKDM4EKMT2ADRD2DRD1
SCHEMBL6130836 0.83 LMNA (0.67) MAOALMNAKDM4EKMT2AKCNN2
SCHEMBL6130861 0.83 LMNA (0.67) MAOALMNAKDM4EKMT2AKCNN2
SCHEMBL16979266 0.83 KMT2A (0.58) LMNAKDM4EKMT2AMEN1ALDH1A1
SCHEMBL15558733 0.82 HCRTR1 (0.45) LMNAKDM4EKMT2AMAPTDRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9815788-B2 Anti-angiogenic compounds THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) 2017-11-14 US disclosed
US-9815788-B2 Anti-angiogenic compounds THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) 2017-11-14 US disclosed
US-20170050930-A1 ANTI-ANGIOGENIC COMPOUNDS UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) 2017-02-23 US disclosed
US-20170050930-A1 ANTI-ANGIOGENIC COMPOUNDS UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) 2017-02-23 US disclosed
EP-2663307-B1 ANTI-ANGIOGENIC COMPOUND UNIV DUBLIN (IE) 2016-08-31 EP disclosed
EP-2663307-B1 ANTI-ANGIOGENIC COMPOUND UNIV DUBLIN (IE) 2016-08-31 EP disclosed
US-9388138-B2 Anti-angiogenic compounds UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) 2016-07-12 US disclosed
US-9388138-B2 Anti-angiogenic compounds UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) 2016-07-12 US disclosed
US-20150218100-A1 ANTI-ANGIOGENIC COMPOUNDS UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) 2015-08-06 US disclosed
US-20150218100-A1 ANTI-ANGIOGENIC COMPOUNDS UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) 2015-08-06 US disclosed
US-8916586-B2 Anti-angiogenic compound University College Dublin—National University of Ireland, Dublin (IE) 2014-12-23 US disclosed
US-8916586-B2 Anti-angiogenic compound University College Dublin—National University of Ireland, Dublin (IE) 2014-12-23 US disclosed
US-8916586-B2 Anti-angiogenic compound University College Dublin—National University of Ireland, Dublin (IE) 2014-12-23 US disclosed
EP-2663307-A1 ANTI-ANGIOGENIC COMPOUND University College Dublin National University Of Ireland, Dublin (IE) 2013-11-20 EP disclosed
US-20130289066-A1 ANTI-ANGIOGENIC COMPOUND UNIVERSITY COLLEGE DUBLIN - NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) 2013-10-31 US disclosed
US-20130289066-A1 ANTI-ANGIOGENIC COMPOUND UNIVERSITY COLLEGE DUBLIN - NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) 2013-10-31 US disclosed
US-20130289066-A1 ANTI-ANGIOGENIC COMPOUND UNIVERSITY COLLEGE DUBLIN - NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) 2013-10-31 US disclosed
WO-2012095836-A1 ANTI-ANGIOGENIC COMPOUND UNIVERSITY COLLEGE DUBLIN - NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) 2012-07-19 WO disclosed
WO-2012095836-A1 ANTI-ANGIOGENIC COMPOUND UNIVERSITY COLLEGE DUBLIN - NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) 2012-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170050930-A1 ANTI-ANGIOGENIC COMPOUNDS VEGFA, FLT4, VHL MAOA 3213/4885LMNA 2551/4885KDM4E 2034/4885
US-20150218100-A1 ANTI-ANGIOGENIC COMPOUNDS VEGFA, FLT4, VHL MAOA 3213/4885LMNA 2551/4885KDM4E 2034/4885
US-20130289066-A1 ANTI-ANGIOGENIC COMPOUND VEGFA, FLT4, FLT1 MAOA 974/4885LMNA 2421/4885KDM4E 1766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.